TY - JOUR
T1 - Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study
AU - BOLD Collaborative Research Group
AU - Burney, Peter
AU - Patel, Jaymini
AU - Minelli, Cosetta
AU - Gnatiuc, Louisa
AU - Amaral, André F.S.
AU - Kocabaş, Ali
AU - Cherkaski, Hamid Hacene
AU - Gulsvik, Amund
AU - Nielsen, Rune
AU - Bateman, Eric
AU - Jithoo, Anamika
AU - Mortimer, Kevin
AU - Sooronbaev, Talant M.
AU - Lawin, Hervé
AU - Nejjari, Chakib
AU - Elbiaze, Mohammed
AU - El Rhazi, Karima
AU - Zheng, Jin Ping
AU - Ran, Pixin
AU - Welte, Tobias
AU - Obaseki, Daniel
AU - Erhabor, Gregory
AU - Elsony, Asma
AU - Osman, Nada Bakri
AU - Ahmed, Rana
AU - Nizankowska-Mogilnicka, Ewa
AU - Mejza, Filip
AU - Mannino, David M.
AU - Bárbara, Cristina
AU - Wouters, Emiel F.M.
AU - Idolor, Luisito F.
AU - Loh, Li Cher
AU - Rashid, Abdul
AU - Juvekar, Sanjay
AU - Gislason, Thorarinn
AU - Al Ghobain, Mohamed
AU - Studnicka, Michael
AU - Harrabi, Imed
AU - Denguezli, Meriam
AU - Koul, Parvaiz A.
AU - Jenkins, Christine
AU - Marks, Guy
AU - Jõgi, Rain
AU - Hafizi, Hasan
AU - Janson, Christer
AU - Tan, Wan C.
AU - Aquart-Stewart, Althea
AU - Mbatchou, Bertrand
AU - Nafees, Asaad Ahmed
AU - Buist, A. Sonia
N1 - Funding Information:
Supported by Wellcome Trust grant 085790/Z/08/Z for the BOLD (Burden of Obstructive Lung Disease) study. The initial BOLD program was funded in part by unrestricted educational grants to the Operations Center in Portland, Oregon, from Altana, Aventis, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor, and the University of Kentucky (Lexington, Kentucky). A full list of local funders can be found at https://www.boldstudy.org.
Funding Information:
GlaxoSmithKline, Merck Sharpe & Dohme, Novartis, Salzburger Gebietskrankenkasse and Salzburg Local Government (Salzburg, Austria); Research for International Tobacco Control, the International Development Research Centre, the South African Medical Research Council, the South African Thoracic Society GlaxoSmithKline Pulmonary Research Fellowship, and the University of Cape Town Lung Institute (Cape Town, South Africa); and Landspítali-University Hospital-Scientific Fund, GlaxoSmithKline Iceland, and AstraZeneca Iceland (Reykjavik, Iceland); GlaxoSmithKline Pharmaceuticals, Polpharma, Ivax Pharma Poland, AstraZeneca Pharma Poland, ZF Altana Pharma, Pliva Kraków, Adamed, Novartis Poland, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, and Agroplon (Cracow, Poland); Boehringer-Ingelheim, and Pfizer Germany (Hannover, Germany); the Norwegian Ministry of Health’s Foundation for Clinical Research, and Haukeland University Hospital’s Medical Research Foundation for Thoracic Medicine (Bergen, Norway); AstraZeneca, Boehringer-Ingelheim, Pfizer, and GlaxoSmithKline (Vancouver, Canada); Marty Driesler Cancer Project (Lexington, Kentucky); Altana, Boehringer Ingelheim (Phil), GlaxoSmithKline, Pfizer, Philippine College of Chest Physicians, Philippine College of Physicians, and United Laboratories (Phil) (Manila, Philippines); Air Liquide Healthcare P/L, AstraZeneca P/L, Boehringer Ingelheim P/L, GlaxoSmithKline Australia P/L, Pfizer Australia P/L (Sydney, Australia), Department of Health Policy Research Programme, Clement Clarke International (London, UK); Boehringer Ingelheim and Pfizer (Lisbon, Portugal), Swedish Heart and Lung Foundation, The Swedish Association against Heart and Lung Diseases, Glaxo Smith Kline (Uppsala, Sweden), Seed Money Grant (PF20/0512), Aga Khan University, and Chiesi Pakistan (Pvt.) Limited (Karachi, Pakistan).
Publisher Copyright:
Copyright © 2021 by the American Thoracic Society
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Rationale: The Global Burden of Disease program identified smoking and ambient and household air pollution as the main drivers of death and disability from chronic obstructive pulmonary disease (COPD). Objectives: To estimate the attributable risk of chronic airflow obstruction (CAO), a quantifiable characteristic of COPD, due to several risk factors. Methods: The Burden of Obstructive Lung Disease study is a cross-sectional study of adults, aged $40, in a globally distributed sample of 41 urban and rural sites. Based on data from 28,459 participants, we estimated the prevalence of CAO, defined as a postbronchodilator FEV1-to-FVC ratio less than the lower limit of normal, and the relative risks associated with different risk factors. Local relative risks were estimated using a Bayesian hierarchical model borrowing information from across sites. From these relative risks and the prevalence of risk factors, we estimated local population attributable risks. Measurements and Main Results: The mean prevalence of CAO was 11.2% in men and 8.6% in women. The mean population attributable risk for smoking was 5.1% in men and 2.2% in women. The next most influential risk factors were poor education levels, working in a dusty job for $10 years, low body mass index, and a history of tuberculosis. The risk of CAO attributable to the different risk factors varied across sites. Conclusions: Although smoking remains the most important risk factor for CAO, in some areas, poor education, low body mass index, and passive smoking are of greater importance. Dusty occupations and tuberculosis are important risk factors at some sites.
AB - Rationale: The Global Burden of Disease program identified smoking and ambient and household air pollution as the main drivers of death and disability from chronic obstructive pulmonary disease (COPD). Objectives: To estimate the attributable risk of chronic airflow obstruction (CAO), a quantifiable characteristic of COPD, due to several risk factors. Methods: The Burden of Obstructive Lung Disease study is a cross-sectional study of adults, aged $40, in a globally distributed sample of 41 urban and rural sites. Based on data from 28,459 participants, we estimated the prevalence of CAO, defined as a postbronchodilator FEV1-to-FVC ratio less than the lower limit of normal, and the relative risks associated with different risk factors. Local relative risks were estimated using a Bayesian hierarchical model borrowing information from across sites. From these relative risks and the prevalence of risk factors, we estimated local population attributable risks. Measurements and Main Results: The mean prevalence of CAO was 11.2% in men and 8.6% in women. The mean population attributable risk for smoking was 5.1% in men and 2.2% in women. The next most influential risk factors were poor education levels, working in a dusty job for $10 years, low body mass index, and a history of tuberculosis. The risk of CAO attributable to the different risk factors varied across sites. Conclusions: Although smoking remains the most important risk factor for CAO, in some areas, poor education, low body mass index, and passive smoking are of greater importance. Dusty occupations and tuberculosis are important risk factors at some sites.
KW - Burden of Obstructive Lung Disease (BOLD) study
KW - Chronic airflow obstruction
KW - Multinational study
KW - Population-attributable risk
UR - http://www.scopus.com/inward/record.url?scp=85107550887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107550887&partnerID=8YFLogxK
U2 - 10.1164/rccm.202005-1990OC
DO - 10.1164/rccm.202005-1990OC
M3 - Article
C2 - 33171069
AN - SCOPUS:85107550887
SN - 1073-449X
VL - 203
SP - 1353
EP - 1365
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 11
ER -